Kelsey Goodwin
Stock Analyst at Guggenheim
(1.68)
# 2,325
Out of 4,667 analysts
15
Total ratings
50%
Success rate
-9.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $8 | $2.49 | +221.29% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $91.17 | +15.17% | 2 | Sep 16, 2024 | |
| URGN UroGen Pharma | Initiates: Buy | $40 | $11.45 | +249.34% | 1 | Aug 22, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $3.28 | - | 1 | Jul 31, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $3.11 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $87.22 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $40.14 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $8.14 | - | 1 | Oct 31, 2022 | |
| IPSC Century Therapeutics | Initiates: Buy | $15 | $1.26 | +1,090.48% | 1 | Oct 31, 2022 |
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.49
Upside: +221.29%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $91.17
Upside: +15.17%
UroGen Pharma
Aug 22, 2024
Initiates: Buy
Price Target: $40
Current: $11.45
Upside: +249.34%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.28
Upside: -
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.11
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $87.22
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $40.14
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $8.14
Upside: -
Century Therapeutics
Oct 31, 2022
Initiates: Buy
Price Target: $15
Current: $1.26
Upside: +1,090.48%